Physician profile
Shaker Itani
NPI 1538193826
$52,043.10
in general payments reported to CMS, 2019-2025
18 companies · $85.16 in 2025
The $85.16 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $2,855 · 2021: $402 · 2022: $10K · 2023: $32K · 2024: $6,425 · 2025: $85.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Travel and Lodging: $3,586 · Food and Beverage: $1,903 · Education: $36.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,500.00 |
| Travel and Lodging | $3,585.65 |
| Food and Beverage | $1,903.34 |
| Education | $36.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $48,235.19 | 2021-2024 | Kimyrsa, Vabomere, Rezzayo |
| Insmed, INC. | $2,342.39 | 2020 | |
| Cipla USA INC. | $377.00 | 2019 | |
| Allergan, INC. | $255.30 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $191.72 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $175.52 | 2020-2024 | Zerbaxa, Dificid |
| Astellas Pharma US INC | $99.54 | 2020-2025 | Cresemba |
| Viiv Healthcare Company | $99.10 | 2020-2024 | Dovato |
| Nabriva Therapeutics, Plc | $56.42 | 2020 | |
| Abbvie INC. | $48.02 | 2021-2024 | |
| Shionogi INC | $37.62 | 2023-2024 | Fetroja |
| Vertex Pharmaceuticals Incorporated | $34.42 | 2025 | |
| Theratechnologies INC. | $17.89 | 2020 | |
| La Jolla Pharmaceutical Company | $15.88 | 2023 | Giapreza |
| Paratek Pharmaceuticals, INC. | $15.67 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $14.83 | 2020 | |
| Oxford Immunotec USA INC | $13.97 | 2020 | |
| Napo Pharmaceuticals INC | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaker Itani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.